Career Development Program The Lymphoma SPORE Career Development program, based on the strong infrastructure for career development that has been a long tradition at both the University of Rochester and the University of Arizona, will provide comprehensive training and education to new investigators committed to careers in translational research in lymphoma. The goal of the SPORE Career Development Program will be to provide the necessary support, mentorship and research environment to enable young faculty to establish a translational research focus and independent funding in lymphoma.
The specific aims of the Career Development Program are to: establish an environment that stimulates and facilitates multidisciplinary interactions among new lymphoma investigators, particularly minorities and women, and provides integrated research and education career development opportunities within a strong infrastructure of mentoring. The program's educational component includes: lymphoma-related educational seminars (videocast to all SPORE participants), skill building workshops (webcast) through the CTSI;master's degree in clinical investigation or translational research (visiting trainees);and intensive grant writing advisement/collaboration (individualized). A detailed, tailored mentoring plan will be implemented for each trainee since access to a strong mentor is critical to early career success. Funding will also be provided for costs related to the conduct of a translational study. A specific plan for program governance and implementation, trainee application, selection and evaluation, and evaluation of global program outcomes is outlined. The future expansion and success of translational research in lymphoma depends upon the support and enhancement of career development efforts that target individuals interested in hematologic malignancies and assure that they have continuous access to superb physician scientists. The proposed program will contribute to this important need.
|Holkova, Beata; Zingone, Adriana; Kmieciak, Maciej et al. (2016) A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22:1067-75|
|Akhenblit, Paul J; Hanke, Neale T; Gill, Alexander et al. (2016) Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI. Mol Imaging 15:|
|Holkova, Beata; Kmieciak, Maciej; Bose, Prithviraj et al. (2016) Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma 57:635-43|
|Zhou, L; Zhang, Y; Chen, S et al. (2015) A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 29:807-18|
|Kiebala, Michelle; Skalska, Jolanta; Casulo, Carla et al. (2015) Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol 43:89-99|
|Jaramillo, Melba C; Briehl, Margaret M; Batinic-Haberle, Ines et al. (2015) Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. Free Radic Biol Med 83:89-100|
|Chen, Liu Qi; Howison, Christine M; Spier, Catherine et al. (2015) Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leuk Lymphoma 56:1432-9|
|Kelly, Jennifer L; Salles, Gilles; Goldman, Bryan et al. (2015) Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol 33:1482-90|
|Chen, Shuang; Zhang, Yu; Zhou, Liang et al. (2014) A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124:2687-97|
|Lee, Kristy; Hart, Matthew R; Briehl, Margaret M et al. (2014) The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma. Int J Oncol 45:439-47|
Showing the most recent 10 out of 112 publications